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Incretin analogues and inhibitors of the breakdown of endogenous incretins are novel classes 
of antidiabetic drugs that increase glucose-stimulated insulin secretion in rodents and 
humans.  Objectives were to test whether the GLP-1 analogues exenatide (E), exenatide 
extended-release (E e-r) and the DPP-4 inhibitor sitagliptin (S) can be safely used in cats, to 
identify the most effective drug and to test the effects of prolonged administration of E e-r. 
E was given to three cats at 0.2-2μg/kg, q12h, subcutaneously, for 5 days. E e-r was given to 
three cats at 40-400μg/kg, subcutaneously, once. S was given to three cats at 1-10mg/kg, 
q24h, orally, for 5 days. Five days after initiation of treatment, meal response tests (MRT) 
were performed and glucose, insulin and glucagon areas under the curve (AUC) calculated. 
Prolonged E e-r treatment was tested in three cats each at 100 and 200μg/kg, q7d, for 5 
weeks, followed by MRT. Compared to treatment-naïve cats, E increased insulin AUC by 
224%, 258%, 331% and 93%, E e-r by 127, 169, 178 and 95%, and S by 32%, 69%, 62%, and 
43%, respectively. Glucose and glucagon AUC were unaffected by drug or dose. E e-r at 
200μg/kg induced a more pronounced enhancement of insulin secretion than at 100μg/kg. The 
three tested drugs are safe to use in cats and enhance insulin secretion. Incretin-based therapy 
may represent a novel treatment option for management of diabetic cats. 
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Inkretin-Analoga und Inhibitoren des Abbaus endogener Inkretine sind neue Klassen 
antidiabetischer Medikamente, die die glukosestimulierte Insulinsekretion bei Ratten und 
Menschen steigern. Ziele der Arbeit waren es, zu untersuchen, ob die GLP-1 Analoga 
Exenatid (E), Exenatid extended-release (E e-r) und der DPP-4 Inhibitor Sitagliptin (S) bei 
Katzen sicher angewendet werden können, das wirksamste Präparat zu identifizieren und die 
Langzeitwirkung von E e-r  zu evaluieren. Jeweils drei Katzen erhielten E über 5 Tage (0.2-
2μg/kg, q12h) subkutan, E e-r einmalig (40-400μg/kg) subkutan und S über 5 Tage (1-
10mg/kg, q24h) peroral. Fünf Tage nach Behandlungsbeginn wurden 
Mahlzeitenreaktionstests durchgeführt und Flächen unter der Kurve (Areas under the curve; 
AUC) für Glukose, Insulin und Glukagon kalkuliert. Die Langzeitwirkung von E e-r wurde 
bei drei Katzen während 5 Wochen (100 und 200μg/kg, q7d) untersucht. Verglichen mit den 
unbehandelten Katzen steigerte E die Insulin AUC um 224%, 258%, 331% und 93%, E e-r 
um 127%, 169%, 178% und 95%, und S um 32%, 69%, 62%, und 43%. Die AUC von 
Glukose und Glukagon wurden durch die Medikamente nicht beeinflusst. E e-r stimulierte die 
Insulinsekretion in der Dosierung von 200μg/kg ausgeprägter als mit 100μg/kg. Die drei 
untersuchten Medikamente können bei Katzen sicher angewendet werden und führen zu einer 
Steigerung der Insulinsekretion. Die Inkretin-Therapie könnte eine neue Behandlungsoption 
für Katzen mit Diabetes mellitus darstellen. 
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Abstract 
Incretin analogues and inhibitors of the breakdown of endogenous incretins are novel classes 
of antidiabetic drugs that increase β-cell proliferation and glucose-stimulated insulin secretion 
in rodents and humans.  Here, we tested whether the glucagon-like peptide 1 (GLP-1) 
analogue exenatide, exenatide extended-release and the dipeptidylpeptidase-4 (DPP-4) 
inhibitor sitagliptin can be safely used in cats, to identify the most effective drug and to test 
the effects of prolonged exenatide extended-release administration. Exenatide was given to 
three cats at 0.2-2μg/kg, q12h, subcutaneously, for 5 days. Exenatide extended-release was 
given to three cats at 40-400μg/kg, subcutaneously, once. Sitagliptin was given to three cats at 
1-10mg/kg, q24h, orally, for 5 days. Five days after initiation of treatment, meal response 
tests (MRT) were performed and glucose, insulin and glucagon areas under the curve (AUC) 
were calculated. Prolonged exenatide extended-release treatment was tested in three cats each 
at 100 and 200μg/kg, q7d, for 5 weeks, followed by MRT. Compared to treatment-naïve cats, 
exenatide increased insulin AUC by 224%, 258%, 331% and 93%, respectively, exenatide 
extended-release by 127, 169, 178 and 95%, respectively, and sitagliptin by 32%, 69%, 62%, 
and 43%, respectively. Glucose and glucagon AUC were unaffected by drug or dose. 
Repeated administrations of exenatide extended-release at 200μg/kg induced a more 
pronounced enhancement of insulin secretion than at 100μg/kg. The three tested drugs are 
safe to use in cats and enhance insulin secretion. Administration of incretin analogues and 
inhibitors of incretin breakdown may be beneficial in cats with diabetes mellitus. 
 
Key Words: incretins, cats, diabetes mellitus, exenatide, sitagliptin. 
 
Abbreviations: MRT, meal response test; AUC, area under the curve. 
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1. Introduction 
Incretins are gastrointestinal hormones released during food intake that increase insulin 
secretion from β-cells of the pancreas. The two well-described incretins, glucagon-like 
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) share most of 
their beneficial effects on β-cells such as stimulation of insulin biosynthesis, stimulation of β-
cell proliferation, enhanced β-cell survival and suppression of β-cell apoptosis (Farilla et al., 
2003; Li et al., 2003). GLP-1 additionally has a suppressive effect on glucagon secretion from 
pancreatic α-cells as well as various extrapancreatic effects including the slowing of gastric 
emptying and of gastrointestinal motility, induction of satiation, weight loss, and possibly also 
cardiovascular protection (Treiman, 2010; Irwin, 2009; Drucker and Nauck, 2006). 
Biologically active GLP-1 and GIP have short half-lives (2 minutes and 7 minutes, 
respectively) and are rapidly degraded by the enzyme dipeptidylpeptidase-4 (DPP-4) (Baggio 
and Drucker, 2004; Deacon et al., 2000). 
Recently, novel classes of anti-diabetic drugs have been developed that take advantage of the 
glucoregulatory actions of incretins. The incretin-based therapeutics comprise direct GLP-1 
receptor agonists, such as exenatide and liraglutide, that are also known as incretin mimetics, 
and DPP-4-inhibitors, such as sitagliptin, that reduce the degradation of endogenous GLP-1, 
the so called incretin enhancers. Different formulations of the GLP-1 receptor agonist 
exenatide exist, requiring either a twice daily (short-acting formulation, e.g. exenatide) or 
once weekly application (long-acting formulation, e.g. exenatide extended-release). Both drug 
classes of incretin mimetics and enhancers have been shown to increase β-cell proliferation 
and glucose-stimulated insulin secretion in rodents and humans, and are successfully used in 
the treatment of human type 2 diabetes (Blevins et al, 2011; Madsbad et al., 2011; Nauck, 
2011; Drucker, 2009; Amori et al., 2007).  
Because it is assumed that the pathogenesis of diabetes in most cats is similar to human type 2 
diabetes, it can be hypothesized that incretin-based agents could also represent an interesting 
 8 
therapeutic option in cats (Reusch and Padrutt, 2013). There is only limited data available on 
the incretin system and the use of incretins in cats. The existence of a physiological incretin 
effect has been demonstrated recently by showing that a larger amount of glucose was 
tolerated without development of hyperglycaemia when given orally and therefore passing 
through the gastrointestinal tract as compared to direct intravenous infusion of glucose. 
However, the glucose-dependent insulinotropic effect appeared to be much lower than that 
reported in other species (Gilor et al., 2011a; Gilor et al., 2011b). Further investigation of the 
incretin system in cats showed a rapid increase of insulin and GLP-1 concentrations after the 
administration of oral glucose (Hoenig et al., 2011). To the authors' knowledge, only the uses 
of the GLP-1 receptor agonist exenatide and of the DPP-4 inhibitor NVP-DPP728 have been 
evaluated in cats prior to this study. It had been shown that exenatide, given once at 1 μg/kg, 
has a glucose-dependent stimulatory effect on insulin secretion and a pronounced effect on 
insulin secretion during normoglycemia in cats (Gilor et al., 2011a). The DPP-4 inhibitor 
NVP-DPP728 showed significant effects to lower plasma glucagon and to enhance insulin 
secretion (Furrer et al., 2010). 
To assess and compare the safety and efficacy of the two short- or long-acting GLP-1 receptor 
agonists exenatide (Byetta, Amylin Pharmaceuticals Inc., San Diego, CA) and exenatide 
extended-release (Bydureon, Amylin Pharmaceuticals Inc., San Diego, CA) and of the DPP-4 
inhibitor sitagliptin (Januvia, Merck Sharp & Dohme Corp., Whitehouse Station, NJ), and to 
identify their most effective doses, a dose-escalation study was conducted in healthy cats. In 
addition, the effect of a prolonged administration of exenatide extended-release was 
investigated. 
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2. Materials and methods 
2.1. Animals 
Two groups of healthy domestic shorthair cats were used. The first group, consisting of nine 
male cats with a median age of 30 months (range: 24–30) and a median body weight of 5.6 kg 
(range: 4.8–5.8) was used for the dose-escalation study with exenatide, exenatide extended-
release and sitagliptin. The second group, consisting of six male cats with a median age of 13 
months (range: 13–15) and a median body weight of 5.1 kg (range: 4.9–5.6) was used to test 
the prolonged administration of exenatide extended-release. The cats were group-housed, had 
free access to water and were fed twice daily at 08:00 am and 06:00 pm with a commercial 
dry food diet (Adult Indoor, Hill’s Pet Nutrition Inc., Topeka, KS). Environmental enrichment 
and social contact were provided on a daily basis. The experiment was approved by the 
Veterinary Office of the Canton Zurich, Switzerland (nr 122/2011). 
Well-being and safety of treatments were assessed in all cats twice daily throughout the 
experiment and for an additional week thereafter by physical examination and measurement 
of body weight, by monitoring appetite, food and water intake, and by recording possible 
clinical side effects. With regard to the latter, particular attention was paid to those of the 
gastrointestinal tract, including vomiting, soft stools and diarrhoea, because similar side 
effects are frequently reported in humans (Holst, 2012; Campbell, 2011). Quality of stools 
was determined according to the Purina Fecal Scoring System 
(www.purinaveterinarydiets.com). Because DPP-4 inhibitors may predispose to cystitis and 
nasopharyngitis in humans (Amori et al., 2007) clinical signs of the urinary tract, such as 
stranguria and pollakiuria, and of the upper respiratory tract, such as sneezing and nasal 
discharge, were also noted in individual medical records for each cat. 
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2.2. Blood sampling 
One week before starting the experiment, a 5 ml blood sample was obtained from the jugular 
vein in awake animals. Blood samples were collected to perform haematological and serum 
biochemical profiles and to verify the health status of the cats. During the experiment, blood 
samples were taken via a jugular catheter to minimize stress reactions of the cats. Jugular 
catheters were placed by Seldinger technique under general anaesthesia on each day of meal 
response testing (Seldinger 1953). The animals were fasted overnight (from 06:00 pm on the 
evening prior to MRT) to ensure a minimal risk of aspiration of gastric contents during 
anesthesia for jugular catheter placement, according to AAHA Anesthesia Guidelines for 
Dogs and Cats (Bednarski et al., 2011). To insert the catheter, sedation was obtained with 
intramuscular butorphanol (Morphasol®-4, Dr. E. Graeub AG, Bern, Switzerland) at 2 mg/kg 
and the α2-adrenoceptor agonist medetomidine (Domitor®, ProVet AG, Lyssach, 
Switzerland) at 5 μg/kg, and general anaesthesia was maintained with intravenous propofol 
(Propofol 1% MTC Fresenius, Fresenius Kabi AG, Bad Homburg, Germany) at 6-8 mg/kg. 
After implantation of the jugular catheters, atipamezol, a potent, selective and specific 
antagonist of both centrally and peripherally located α2-adrenoceptors was administered at 5 
μg/kg (Antisedan®, ProVet AG, Lyssach, Switzerland) to reverse the effects of medetomidine 
and the cats regained full consciousness within 5-10 minutes. 
Blood samples were collected during each meal response test (MRT) and were used to 
measure plasma concentrations of insulin and glucagon. After collection, samples were 
immediately transported to the laboratory on ice, cold-centrifuged and the EDTA plasma was 
stored at -80 °C until later analysis. Insulin was measured with the Mercodia ELISA # 10-
1233-01 (Mercodia AB, Uppsala, Sweden) and glucagon with the rat-glucagon ELISA kit 
Wako # 297-57101 (Wako Chemicals GmbH, Neuss, Germany), previously validated for use 
in cats by our laboratory. Capillary blood glucose was measured with the portable glucose 
meter AlphaTRAK (Abbott Laboratories, Abbott Park, IL) specifically designed for dogs and 
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cats, using samples collected from the inner pinna of the ear. The device has been shown to 
accurately measure blood glucose in cats (Zini et al., 2009). 
 
2.3. Meal response test 
The MRT was performed prior to initiation of treatment and on day 5 of each incretin 
treatment period. The MRT served to assess α- and β-cell function in cats (Furrer et al., 
2010). One hour after regaining full consciousness following the placement of the jugular 
catheters, 2 ml basal blood samples were taken and the cats were offered a test meal (Adult 
Indoor, Hill’s Pet Nutrition Inc., Topeka, KS) comprising 50% of their average daily energy 
requirement (25 g, approximately 130 kcal). The test meals were rapidly ingested (in 1-2 
minutes). Subsequently, 2 ml blood samples were taken from the jugular catheters at 15, 30, 
60, 120 and 300 minutes after food intake. 
 
2.4. Dose-escalation protocol 
Because no data were available regarding exenatide, exenatide extended-release and 
sitagliptin administration in cats, a dose-escalation experiment was conducted for each drug to 
identify the occurrence of possible clinical adverse reactions and to assess their effect on 
insulin and glucagon secretion. After performing a basal MRT prior to treatment, which was 
followed by a 2-week intermission without any medication, treatment was started in all three 
drug groups. Exenatide was given subcutaneously to each of three cats at 0.2, 0.5, 1 and 2 
μg/kg for five consecutive days, twice daily (at 8:00 am and 8:00 pm). Exenatide extended-
release was given subcutaneously to each of three cats at 40, 100, 200 and 400 μg/kg with 
single injections (at 8:00 am on day 1). Sitagliptin was given orally to each of three cats at 1, 
3, 5 and 10 mg/kg for five consecutive days, once daily (at 8:00 am). To prevent 
accumulation of the drugs, every new dose was anticipated by a 2-week washout period. On 
day 5 of each treatment dose of exenatide or sitagliptin, or on day 5 following each injection 
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of exenatide extended-release, MRT were performed starting at 11:00 am in all cats. To assess 
the effects of the drugs, AUC for glucose, insulin and glucagon were compared to values 
before drug administration. 
 
2.5. Prolonged administration of exenatide extended-release 
Evidence from human medicine showed that a steady state plasma level of exenatide-
extended release may only be reached after 6-8 weeks of treatment (Iwamoto et al., 2009; 
Kim et al., 2007). Therefore prolonged administration of exenatide extended-release was also 
performed in the present study in cats. Using the two safest and most effective drug doses 
estimated from the dose-escalation experiment, exenatide extended-release was injected 
subcutaneously to three cats at the dose of 100 μg/kg and to another three cats at the dose of 
200 μg/kg, every seven days, for five consecutive weeks. The MRT was performed five days 
after the last exenatide extended-release administration and AUC for glucose, insulin and 
glucagon were calculated. Values prior to treatment were compared to the values obtained on 
day five (11:00 am) after the last administration of exenatide extended-release. 
 
3. Results 
Drug safety and side effects 
In the nine cats used for the dose-escalation study, mild and self-limiting diarrhoea and 
vomiting occurred in six of nine cats (Table 1). Diarrhoea (scores 5 and 6 of the Purina Fecal 
Scoring System (score 1 to 7)) was documented in six cats (2 with exenatide, 2 with exenatide 
extended-release and 2 with sitagliptin), for a median duration of four days (range: 1-5); 
vomiting was documented in two cats with diarrhoea (1 with exenatide, 1 with exenatide 
extended-release), for one and six days, respectively. In two cats the side effects developed 
during the first day of treatment, and in one cat after the second day of treatment. In three cats 
side effects first occurred with a new dose, on the first day or on the second to fifth day of 
 13 
treatment. In addition, in four of the six cats side effects were also observed during the 2-
week washout period. Of note, in two cats side effects were documented once during the 
experiment and in four cats they occurred several times (median: 5 times, range: 5–7). The 
gastrointestinal adverse reactions were self-limiting; none of the cats needed therapeutic 
intervention and application of the drugs did not have to be discontinued in any of them. 
Other side effects were not documented. General well-being as well as food and water intake 
were not impaired at any time. In the second group of six cats used for the prolonged 
administration of exenatide extended-release, side effects did not occur. Reactions at the 
injection-site were not observed in any of the cats receiving either exenatide or exenatide 
extended-release. 
 
Dose-escalation protocol 
Average glucose AUC after the administration of exenatide, exenatide extended-release and 
sitagliptin were similar to corresponding glucose AUC obtained prior to treatment, 
irrespective of the dose (Tables 2a, 2b, 2c). Hypoglycemia did not occur with any drug. 
All three drugs tested during the dose-escalation protocol enhanced meal-dependent insulin 
secretion, based on MRT. The 4 incremental doses of exenatide increased average insulin 
AUC by 224%, 258%, 331% and 93%, respectively, compared to insulin AUC in treatment 
naïve cats (Table 3a). Exenatide extended-release doses increased average insulin AUC by 
127%, 169%, 178%, 95%, respectively, and sitagliptin increased average insulin AUC by 
32%, 69%, 62%, 43%, respectively (Tables 3b, 3c). 
Exenatide increased and decreased glucagon AUC, whereas exenatide extended-release and 
sitagliptin decreased glucagon AUC, based on MRT. The three lower doses of exenatide 
yielded an average increase of 14%, 35%, 46%, respectively, while the highest dose of 
exenatide decreased glucagon AUC by 14% compared to glucagon AUC obtained in 
treatment-naïve cats (Table 4a). Exenatide extended-release decreased average glucagon AUC 
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by 15%, 8%, 1% and 16%, respectively, and sitagliptin decreased average glucagon AUC by 
34%, 29%, 16% and 22%, respectively (Tables 4b, 4c). 
 
Prolonged administration of exenatide long-acting 
Average glucose AUC after the prolonged administration of exenatide extended-release was 
similar to glucose AUC obtained prior to treatment, with either dose (Table 5a). 
Hypoglycemia was not documented. 
Based on MRT, the prolonged administration of exenatide extended-release 100 μg/kg/week 
for 5 weeks decreased average insulin AUC by 8% compared to treatment-naïve cats (Table 
5b); of note, although insulin AUC was reduced, the insulin AUC from 0 to 120 minutes in 
treated cats was 40% higher than in untreated cats.. Exenatide extended-release at the dose of 
200 μg/kg/week for 5 weeks increased average insulin AUC during MRT by 15% (Table 5b) 
and the insulin AUC from 0 to 120 minutes in treated cats was 116% higher than in untreated 
cats. 
Based on MRT, the prolonged administration of exenatide extended-release 100 μg/kg/week 
for 5 weeks increased average glucagon AUC by 253 % in comparison to treatment-naïve 
cats. Exenatide extended-release at the dose of 200 μg/kg/week for 5 weeks increased average 
glucagon AUC by 3% (Table 5c). 
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4. Discussion 
The results of the dose-escalation protocol showed that exenatide, exenatide extended-release 
and sitagliptin were all able to enhance insulin secretion in healthy cats. The GLP-1 agonists 
exenatide and exenatide extended-release showed more pronounced effects than the DPP-4 
inhibitor sitagliptin which is consistent with findings in humans, where GLP-1 agonists are 
superior in achieving good glycaemic control (Karagiannis et al., 2012; Nauck, 2011). GLP-1 
leads to an increase of insulin secretion in humans due to direct effects on pancreatic β-cells, 
including a stimulation of insulin biosynthesis and of β-cell proliferation, as well as enhanced 
β-cell survival and resistance to apoptosis (Farilla et al., 2003; Li et al., 2003). Because most 
diabetic cats suffer from a disease that shares many similarities to human type 2 diabetes 
(Reusch and Padrutt, 2013), the enhanced insulin secretion achieved in healthy cats may 
suggest that exenatide, exenatide extended-release and sitagliptin could be beneficial also in 
diabetic cats, possibly improving β-cell function or viability via one or more of the 
mechanisms demonstrated in humans. 
Prolonged administration of exenatide extended-release enhanced postprandial insulin 
secretion more than in untreated cats, at both 100 and 200 μg/kg/week. The effects on insulin 
secretion were more pronounced at the higher dose, where the meal-induced enhancement of 
insulin concentration of the AUC from 0 to 120 minutes was 116% higher after the 5-week 
application of the drug than in treatment naïve cats. The comparison of AUCs from 0 to 120 
minutes of untreated vs. treated cats (40% increase of AUC for 100 μg/kg and 116% increase 
for 200 μg/kg) showed a pronounced post prandial enhancement of insulin secretion for both 
doses, whereas the total AUC of insulin was less affected by exenatide extended-release, with 
a mild increase at 200 μg/kg and even a slight decrease with 100 μg/kg. The reason for the 
mild effect on insulin AUC is probably due to the fast insulin drop observed after the 
postprandial insulin peak in treated cats. This drop in insulin secretion after the time period of 
120 minutes could possibly be explained by counterregulatory mechanisms against 
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hypoglycaemia in healthy cats. In dogs, counterregulatory elevations of glucagon, cortisol and 
lactate have been observed after portal administration of GLP-1 (Ionut et al., 2005), and 
studies in humans show that in the presence of exenatide there are strongly preserved 
counterregulatory mechanisms during hypoglycemia (Degn et al., 2004). Although during the 
present study hypoglycemia did not occur, similar counterregulatory effects might have 
prevented impending substantial drops in blood glucose in the healthy cats. 
A tachyphylactic effect of the tested drugs during the dose-escalation protocol and the 
prolonged administration of exenatide extended-release seems rather unlikely. Also after 
chronic administration of GPL-1 receptor agonists, despite sustained elevations in the 
circulating levels of the drug, no evidence for tachyphylaxis or clinically significant receptor 
desensitization has been observed in human clinical studies (Nauck et al., 1996, Hargrove et 
al., 1995). Exendin 4 has been found to be more potent than native GLP-1 in producing GLP-
1 receptor desensitization in vitro, but chronic exposure to exendin 4 in normal or transgenic 
mice was not associated with significant downregulation of GLP-1 receptor–dependent 
responses coupled to glucose homeostasis (Baggio et al., 2004). 
The strong effects on insulin peak secretion and the absence of any side effects as well as the 
convenient therapy regimen of a once weekly injection may make the prolonged 
administration of exenatide extended-release a more favourable option over exenatide and 
sitagliptin in diabetic cats. 
Besides the effect of GLP-1 on insulin, incretins also decrease glucagon secretion from 
pancreatic α-cells (Drucker and Nauck, 2006). In diabetic humans, GLP-1 agonists as well as 
DPP-4 inhibitors reduce glucagon secretion. In a previous study in healthy cats, the 
administration of the DPP-4 inhibitor (NVP-DPP728) yielded a significant reduction of 
plasma glucagon concentrations after a MRT (Furrer et al., 2010). Consistent with these 
findings, results of the present dose-escalation protocol showed a decrease of glucagon 
secretion with sitagliptin and exenatide extended-release. Differently, with exenatide a dose-
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dependent increase of glucagon followed by a decrease was observed. The reason for this 
result is unclear. It is known that in the case of hypoglycemia, counterregulatory secretion of 
glucagon is preserved even with pharmacological concentrations of GLP-1 (Drucker and 
Nauck, 2006). Although the measured glucose values during MRT did not drop, it might be 
that the observed increase of glucagon secretion was part of the physiologic compensation 
against hypoglycaemia in healthy cats. Furthermore, the decrease of glucagon demonstrated 
with the highest exenatide dose (i.e., 2 μg/kg) may be explained by the fact that the same dose 
lead to the lowest increase of insulin concentration, perhaps reducing the counterregulatory 
effect on glucagon. 
Similar to most doses of exenatide, prolonged administration of exenatide extended-release 
increased glucagon secretion, in particular at the lower dose (100 μg/kg). The reason for the 
increased glucagon, which contrasts the effect of exenatide extended-release given for a short 
period during the dose-escalation protocol, is uncertain. At 100 μg/kg of exenatide extended-
release, the cats showed lower insulin secretion, making the above hypothesis of 
counterregulation provided for the highest dose of exenatide unlikely. The present findings of 
this study cannot provide evidence of a suppressive effect of exenatide, exenatide extended-
release, and sitagliptin on glucagon concentrations. Further studies are required to assess the 
effects of incretin mimetics and enhancers on glucagon. 
The results of glucose AUC obtained after treatment did not differ from those achieved prior 
to treatment with any of the drugs tested, and no lowering effect on fasting glucose was 
observed. Since only healthy animals were used for this study, counteracting hormones, such 
as glucagon but also norepinephrine (Rand et al., 2008), might have played a substantial role 
in preventing hypoglycaemia or even slight drops in blood glucose concentrations. A recent 
study in healthy rats showed an unexpected rise of glucose levels after acute administration of 
exenatide caused by stimulation of the sympathetic nervous system (Perez-Tilve et al., 2010). 
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A similar effect might be present also in healthy cats, possibly explaining the lack of glucose 
lowering effects of incretins under our test conditions, in healthy normoglycemic cats. 
As an additional benefit to improved glycaemic control, the GLP-1 agonists exenatide and 
exenatide extended-release are associated with weight loss in diabetic patients, whereas DPP-
4 inhibitors seem to be weight neutral (Blevins et al., 2011; Madsbad et al., 2011; Drucker et 
al., 2008,). Body weight of all the cats was assessed on a weekly basis and remained stable 
during the study period. It cannot be excluded that longer duration of treatment might also 
have caused weight loss in cats. 
The results of this study show that exenatide, exenatide extended-release and sitagliptin can 
all cause gastrointestinal side effects in cats. In particular, cats enrolled in the dose-escalation 
protocol showed mild and self-limiting diarrhoea and vomiting that were independent from 
the drug and dose given. Differently, exenatide extended release administered to cats over a 
period of 5 weeks did not appear to cause gastrointestinal side effects. 
Exenatide is generally well tolerated in humans, although commonly reported side effects 
include mild gastrointestinal symptoms like nausea, vomiting and diarrhoea, which usually 
resolve after 4 to 8 weeks of treatment (Holst, 2012; Campbell, 2011). Gastrointestinal 
symptoms are dose-dependent and gradual dose increase can be used to lessen symptoms 
(Fineman et al., 2004). In the present study, clinical signs with exenatide were similar to 
humans, but their occurrence did not appear to be dose-dependent, at least within the dose 
range tested here, possibly suggesting a species-specific difference. 
The frequency of gastrointestinal side effects with exenatide extended-release is lower than 
with exenatide, but the former commonly causes injection-site reactions in humans (Blevins 
et al., 2011; Madsbad et al., 2011; Drucker et al., 2008). In cats, side effects with exenatide 
extended-release were few in the dose-escalation protocol and none during the prolonged 
administration, similar to humans. Obvious reactions at the injection site were not 
documented, suggesting that exenatide extended-release would be very safe if used in diabetic 
 19 
cats. DPP-4 inhibitors like sitagliptin are known to cause less gastrointestinal side effects than 
GLP-1 agonists, but are associated with an increased risk of cystitis, nasopharyngitis and 
headache (Amori et al., 2007). None of the cats of the study showed respiratory signs or 
urinary tract disease. 
Limitations of the study that need to be mentioned are the small number of cats included that 
prevented inferential statistical analysis to be performed, as well as the lack of blood samples 
collected after treatment to identify possible side effects on haematological and serum 
biochemical profiles. Because of the intensive study protocol and multiple blood sampling of 
considerable blood volumes, the allowed number of research animals was limited to 9 by the 
veterinary office. To prevent anemia, on the grounds of animal welfare considerations as well 
as to preclude potential negative effects of anemia on the test results, the study period was 
limited to the described 4 incremental doses of each drug. 
In conclusion, exenatide, exenatide extended-release and sitagliptin can be safely used and are 
able to enhance insulin secretion in healthy cats. The use of incretin-based therapy may 
represent a novel treatment option for management of diabetic cats, and warrants further 
studies in a larger population of healthy cats, as well as diabetic cats. 
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Figure captions 
 
Table 1. Overview of gastrointestinal side effects due to exenatide, exenatide extended-
release and sitagliptin. D= diarrhoea, V= vomitus. 
 
Table 2. Glucose AUC concentrations with exenatide (a), exenatide extended-release (b) and 
sitagliptin (c) at incremental doses. The areas are expressed in (mmol/L) x minutes. 
 
Table 3. Insulin AUC concentrations with exenatide (a), exenatide extended-release (b) and 
sitagliptin (c) at incremental doses. The areas are expressed in (pmol/L) x minutes. 
 
Table 4. Glucagon AUC concentrations with exenatide (a), exenatide extended-release (b) 
and sitagliptin (c) at incremental doses. The areas are expressed in (ng/L) x minutes. 
 
Table 5. Glucose (a), insulin (b) and glucagon (c) AUC concentrations with exenatide 
extended-release at 100 μg/kg/week and 200 μg/kg/week for five weeks. The areas are 
expressed in (mmol/L) x minutes. 
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